This website is intended for healthcare professionals from the United Kingdom only. Adverse event reporting information can be found at the bottom of the page.

Logo logo

Helping people with Parkinson’s get back on with their day

Purple swoosh

INBRIJA® - rapid, reliable relief in 10 minutes1,2

UPDRS Part III score change from 0‑60 minutes post dose at week 121

Patients experiencing OFF episodes can quickly regain control of their lives, enabling them to stay socially connected and active.

  • Inhaled LD bypasses the gut for rapid, consistent bioavailability2
  • Can be taken when needed, up to 5 times per day3
  • No adjustment of baseline medication needed2

INBRIJA®: On-demand therapy that bypasses the gut

INBRIJA® bypasses the gut, providing rapid and reliable relief from OFF episodes.2

Administered via the pulmonary route, INBRIJA® enables consistent absorption.3

Avoids variability caused by GI tract absorption3

Allows for use when needed2

INBRIJA® delivers consistent plasma concentrations, starting within 10 minutes3

With its predictable pharmacokinetic profile INBRIJA® delivers consistent concentrations of levodopa within 10 minutes.3*

INBRIJA® 84 mg† (n=20)3

Oral CD/LD 25/100 mg (n=17)3

Plasma concentration of levodopa in INBRIJA® vs. oral CD/LD* after a high-fat, high-protein meal3

*Results from a randomised, open-label, 2-way crossover study evaluating the pharmacokinetics of a single inhaled dose of INBRIJA® 84 mg, administered with oral carbidopa 25 mg, and a single ingested dose of CD/LD 25/100 mg in fed state in PwP who were regularly taking oral CD/LD.1†‡

†INBRIJA® 84 mg co-administered with 25 mg oral carbidopa for true pharmacokinetic comparison to levodopa.2

CD; carbidopa; LD, levodopa.

References:

  1. 1. LeWitt PA, Hauser RA, Pahwa R, et al; SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019;18:145-154.
  2. 2. Isaacson SH, Pagan FL, Lew MF, Pahwa R. Should “on-demand” treatments for Parkinson’s disease OFF episodes be used earlier? Clin Park Relat Disord. 2022;7:100161.
  3. 3. Safirstein BE, Ellenbogen A, Zhao P, Henney HR 3rd, Kegler-Ebo DM, Oh C. Pharmacokinetics of inhaled levodopa administered with oral carbidopa in the fed state in patients with Parkinson’s disease. Clin Ther. 2020;42:1034-1046.
  4. 4. INBRIJA® Summary of Product Characteristics.
M-INB-UK-0050
Date of preparation: December 2025

This website contains information about INBRIJA® (levodopa inhalation powder)

I am a member of
the public

M-INB-UK-0047
Date of preparation: December 2025